The S&P/ASX 200 Index (ASX: XJO) is home to 200 of the largest companies on the Australian share market.
While not all of these shares are necessarily in the buy zone, a number of them jump out as potential options.
Two that come highly rated are listed below. Here's why they could be in the buy zone:
Aristocrat Leisure Limited (ASX: ALL)
Aristocrat Leisure is one of the world's leading gaming technology companies, specialising in both poker machines and mobile games.
Aristocrat's poker machines are some of the most sought after in the world and have been winning market share globally consistently in recent years. While the pandemic has hit this segment hard because of casino closures and social distancing initiatives, it looks well-placed for growth once the crisis passes.
In the meantime, its digital business continues to perform strongly and generate significant recurring revenues. And with new releases strengthening its offering, the segment also looks well-positioned for growth.
Analysts at Citi are positive on its long term prospects. They note that 2020 has been a difficult year, but believe the company will bounce back strongly. Citi has a buy rating and $40.60 price target on its shares.
CSL Limited (ASX: CSL)
Another ASX 200 share to look at is this biotherapeutics giant. CSL appears to be in a position for growth over the long term due to increasing demand for immunoglobulins and influenza vaccines, its expansive (and growing) plasma collection network, and its lucrative research and development pipeline.
The latter has some very promising therapies under development and is being supported by a material investment each year. In fact, in FY 2021, CSL will be investing approximately ~US$1 billion into its research and development activities. This is on top of a US$922 million investment in FY 2020.
One broker that is positive on the company's prospects is Credit Suisse. It currently has an outperform rating and $325.00 price target on CSL's shares.
